Tscan Therapeutics (TCRX): 10% owner bought, ~$72K

~$72K
Approx. value · 80K sh @ $0.8989: 7.94M
Holds after · shares reported

Traded: Dec 19, 2025
Filed: Dec 23, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

Nov 3, 2025Company filing · Form 8-K · Restructuring, Reg FDAnnounced job cuts, closures or a restructuring, and shared information with investors (and 1 more item)“On November 3, 2025, TScan Therapeutics, Inc. (the “Company”) initiated a prioritization strategy by which the Company will prioritize the clinical development of its heme program, pause further enrollment in its solid tumor Phase 1 trial, and focus preclinical efforts on in vivo engineering for solid tumors and target discovery in autoimmunity.”
Nov 12, 2025Company filing · Form 8-K · ResultsReported its results
Nov 25, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 25, 2025, the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”), upon the recommendation of the Compensation Committee, approved a retention program designed to retain the employees required to support the Company, including a key employee retention program (the “Retention Program”) that provides for cash awards and the potential future grant of equity-based awards to certain…”
Dec 19, 2025 · this disclosureInsider10% owner purchased ~$72K of TCRX shares in the open market

What came next

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Tscan Therapeutics

OQRO holds no insider, Congress, fund or contract record for Tscan Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TCRX page.

Other recent filings by Lynx1 Capital Management LP, 10% owner

The full history of Lynx1 Capital Management LP, 10% owner is on the profile page.

Other disclosures at Tscan Therapeutics

Everything OQRO holds on this company is on its TCRX page.

Tscan Therapeutics (TCRX)10% owner bought ~$72K